CODAGLIO

The CODAGLIO project, that started in September 2016, aimed to combine clinical and health-related quality of life (HRQOL) data of available randomized controlled trials in glioma (i.e., primary brain tumour) patients. The project was a collaboration between the Quality of Life Group, the Brain Tumour Group and the Quality of Life Department. Data of more than 6000 patients was included in the study. With this large dataset the following clinically relevant questions, were addressed: ‘What is the added prognostic value of HRQOL on overall survival and progression-free survival?’ and ‘Are specific symptom clusters associated with overall HRQOL?’. Ultimately, the trade-off between quality and quantity of life of treatment strategies and the question ‘Will a combined analysis of survival and HRQOL data facilitate interpretation on the net clinical benefit of a treatment strategy?’ were addressed.

See publications below.

This study is now closed.

Patients with a glioma, the most prevalent primary malignant brain tumour, demonstrate a high symptom burden and experience many disease-specific symptoms such as cognitive dysfunction and seizures. Although patients receive treatment with surgery, radiotherapy and chemotherapy, current treatment options are not curative. Therefore, the quality of survival is for these patients at least as important as the duration of survival. Because primary brain tumours are relatively rare, and the number of trials that included assessments of health-related quality of life (HRQOL) are limited, it is essential to combine these datasets. By combining these datasets clinically relevant questions can be answered. For example, what specific concurrent symptoms cause a deficit in functioning, as management of these symptoms may result in an improved HRQOL. Also, certain models were used to combine information on the impact of a treatment on both survival and HRQOL. Such information may help physicians to decide which treatment is best for a specific patient.